Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.40USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.40
Open
$4.35
Day's High
$4.50
Day's Low
$4.35
Volume
96,474
Avg. Vol
92,123
52-wk High
$6.45
52-wk Low
$2.58

Summary

Name Age Since Current Position

Richard Williams

71 2014 Independent Chairman of the Board

Dennis Carlo

71 2009 President, Chief Executive Officer, Director

Robert Hopkins

54 2009 Chief Financial Officer, Vice President - Finance

David Marguglio

44 2010 Senior Vice President - Corporate Development, Director

Karen Daniels

62 2009 Vice President - Operations

Gus Fernandez

54 2015 Vice President - Commercial Operations

Thomas Moll

49 2008 Vice President - Research

William Denby

60 2014 Independent Director

Robert Rothermel

71 2014 Independent Director

Mark Gundy

IR Contact Officer

Biographies

Name Description

Richard Williams

Mr. Richard C. Williams is the Independent Chairman of the Board of Adamis Pharmaceuticals Corporation. Since 1989, Mr. Williams has served as the founder and President of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the healthcare industry and pharmaceutical segment. Prior to founding Conner-Thoele Limited in 1989, Mr. Williams served in a number of progressively responsible operational and financial management positions with multinational firms. These firms included American Hospital Supply Corporation, UNC Resources, Abbott Laboratories, Field Enterprises and Erbamont NV. Mr. Williams has served as a director and Vice Chairman of Strategic Planning for King Pharmaceuticals. Prior to King Pharmaceuticals, he served as Chairman and a director of Medco Research before Medco was acquired by King Pharmaceuticals. Mr. Williams has also served as a director of several other public and private companies, several as Chairman, including ISTA Pharmaceuticals, Vysis Pharmaceuticals, Immunemedics, EP Medical and Cellegy Pharmaceuticals, Inc. Mr. Williams served as a director of Cellegy from November 2003 to April 2009, and was Chairman of Cellegy from November 2003 to 2009, when Cellegy merged with Old Adamis, which was then-named Adamis Pharmaceuticals Corporation, and changed its corporate name to Adamis Pharmaceuticals Corporation. Following the merger, Mr. Williams served as Chairman of the Company until June 2009. He served as a director of ISTA Pharmaceuticals from December 2002 to June 2012 and as Chairman of the Board from July 2004 to June 2012, when ISTA was acquired. He was a member of the Listed Company Advisory Committee of the New York Stock Exchange. Mr. Williams received a Bachelor of Arts degree in Economics from DePauw University and a Masters of Business Administration from the Wharton School of Finance.

Dennis Carlo

Dr. Dennis J. Carlo, Ph.D., is President, Chief Executive Officer, Director of Adamis Pharmaceuticals Corporation since April 1, 2009. Dr. Carlo became President, Chief Executive Officer and a director of the Company in April 2009 in connection with the closing of the merger transaction between the Company and the corporation that now is a wholly-owned subsidiary of the Company, Adamis Corporation (“Old Adamis”). Dr. Carlo was a co-founder of Old Adamis and served as its President and Chief Executive Officer, and a director, from October 2006 to April 2009. From 2003 to 2006, he served as president of Telos Pharmaceuticals, a private biotechnology company. From 1982 to 1987, he served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., a pharmaceutical and life science company which was acquired by Eli Lilly & Co in 1986. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberland, founded The Immune Response Corporation, a public biotechnology company, where he served as its President and Chief Executive Officer from 1994 to 2002. Before then, he held various positions with life science companies, including Merck & Co. Dr. Carlo received a B.S. degree in microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. r5th

Robert Hopkins

Mr. Robert O. Hopkins is Chief Financial Officer, Vice President - Finance of Adamis Pharmaceuticals Corporation since April 1, 2009. He joined Old Adamis in April 2007 as Vice President, Finance and Chief Financial Officer. From 2000 to 2004, he was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. In that position he managed financial operations for a corporation that held several hospitals, an extensive life sciences operation and a number of other business units within its portfolio. Mr. Hopkins served as Chief Financial Officer of Veritel Corp. from 1999 and 2000, a biometric software company. He has also served as Chief Operating Officer for Circle Trust Company from 2004 to 2005, during which time he was responsible for corporate reorganization after acquiring a troubled trust company. From 2005 until Mr. Hopkins joined Old Adamis in April 2007, he consulted for Acumen Enterprises providing analysis and business plans for the various projects with which the company was involved. From 1997 to 1999, Mr. Hopkins was Senior Vice President for Finance for the Mariner Post-Acute Network, Atlanta, Georgia. In this position he was responsible for financial management of a division consisting of 12 long-term, acute care hospitals. Among his previous medical-related experience, he has served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. Mr. Hopkins received a B.S. degree in Finance from Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.

David Marguglio

Mr. David J. Marguglio is Senior Vice President - Corporate Development, Director of Adamis Pharmaceuticals Corporation. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009 in connection with the closing of the merger transaction with Old Adamis. Mr. Marguglio was a co-founder of Old Adamis and served as its Vice President of Business Development and Investor Relations, and a director from its inception in June 2006 until April 2009. He became Senior Vice President of Corporate Development in December 2010. From 1996 to 2006, he held various positions with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. From 1993 to 1994, he served as financial counsel for the commercial litigation division of a national law firm. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.

Karen Daniels

Ms. Karen K. Daniels is Vice President - Operations of Adamis Pharmaceuticals Corporation. She has over 30 years of experience in operational and engineering roles across diverse industries including electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. Prior to joining Adamis, Ms. Daniels served as President of Althea Technologies from 2007 to 2009. Althea Technologies is a contract manufacturer for the pharmaceutical industry. She also served as Senior Director of Operations and Logistics for Vidacare, a medical device manufacturer from 2006 to 2007. From 2003 to 2006, she was President of Lambda Power. Ms. Daniels received a B.S. degree from the University of Arizona.

Gus Fernandez

Mr. Gus Fernandez, Pharm.D., MBA, is Vice President - Commercial Operations of the Company. In this role, he will work closely with other senior management members to direct all aspects of commercial sales. Most recently, he served as National Business Director for inVentiv Health Commercial Services where he formed, recruited and retained sales teams. Prior to inVentiv, he was VP of Commercial Development and Operations for Avanir Pharmaceuticals where he was responsible for new product planning and commercial operations. Before Avanir, he held several managing roles over a six year period for Dura Pharmaceuticals including Director of Sales Operations. At Dura, he directed a staff of thirteen which supported over 400 sales professionals. He also spent six years as a sales representative for Eli Lilly & Company.

Thomas Moll

Dr. Thomas Moll, Ph.D., is Vice President - Research of Adamis Pharmaceuticals Corporation. He has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. Prior to joining Adamis, Dr. Moll was Vice President of Research at privately held Telos Pharmaceuticals from 2003 to 2008. From 1998 to 2003 he was Vice President of Immunology at Cardion AG, a privately held German biotech company. Dr. Moll holds a diploma in Biology II from the University of Basel, Switzerland, and received his doctorate degree in Genetics and Biochemistry from the University of Vienna, Austria.

William Denby

Mr. William C. Denby III is an Independent Director of the Company. From 2002-2014, Mr. Denby was Senior Vice President, Commercial Operations at Santarus, Inc. which was acquired by Salix Pharmaceuticals, Ltd. in January of 2014. At Santarus, he directed all commercial functions including Sales, Marketing, Market Research, Customer Service, Managed Care, New Product Planning and other various functions. Prior to Santarus, he was Senior Vice President, Commercial Operations and Senior Vice President, Sales and Marketing at Agouron Pharmaceuticals, Inc. Mr. Denby played leadership roles in the sale of Agouron to Warner Lambert and Santarus to Salix Pharmaceuticals. Earlier in his career, he spent approximately 20 years in various leadership management roles at Marion Merrell Dow, Inc., a pharmaceutical company. Mr. Denby has a Bachelor of Arts degree in English and Business from State University of New York at Fredonia and a Masters of Business Administration from Rockhurst College.

Robert Rothermel

Mr. Robert B. Rothermel is an Independent Director of Adamis Pharmaceuticals Corporation. Mr. Rothermel is a partner with a private investment and management firm, CroBern Management Partnership, which works within the health care industry. Currently, he serves as a board member and chairman of the audit committee of Medcor Inc., a private healthcare company, and has also served as a board member of Cerescan, a private brain imaging company, as well as other CroBern portfolio companies. Prior to CroBern, Mr. Rothermel spent 37 years with Deloitte & Touche, and served as a Partner and Global Managing Director of the Enterprise Risk Services practice. He also served as a member of Deloitte & Touche’s Board of Directors, the firm’s Global Assurance and Advisory Management Committee, the U.S. Management Committee and chaired the firm’s Partner Compensation Committee. He also served as a director of Cellegy from January 2004 until its merger with Adamis in April 2009 and was Chair of the audit committee of Cellegy. Following the merger, Mr. Rothermel served as a director and Chair of the audit committee of the Company until June 2009. Mr. Rothermel has a Bachelor of Science degree in Business Administration from Bowling Green State University.

Mark Gundy

Basic Compensation